The healthcare services firm targets leverage below 2x while reporting $3.9 billion in Q2 2026 revenue, up 23% year-over-year.
BrightSpring Health Services projected adjusted EBITDA of $820M-$845M for 2026, aiming to reduce leverage below 2x. The outlook follows stronger-than-expected Q2 2026 results, with revenue reaching $3.9 billion, a 23% increase from the prior year.
The company’s performance exceeded baseline expectations, driven by growth across its segments. Prior quarters had not disclosed specific EBITDA targets for 2026, making this guidance a new benchmark for investors.
Management expressed satisfaction with the quarter’s results but did not detail immediate market reactions in the earnings call.